Please login to the form below

Not currently logged in
Email:
Password:

Fishawack undergoes management buyout

Oliver Dennis and Dominic Miller will continue to lead the communications firm

Fishawack CEO Oliver DennisUK medical communications agency Fishawack has undergone a management buyout that it says will enable it to accelerate its 'buy and build' strategy.

The deal values the Knutsford, Cheshire business at £38m and will see it continue to be led by founders Oliver Dennis (pictured) and Dominic Miller.

Fishawack, which provides med comms, market access and pharmacovigiliance services, was founded in 2001 and now employs over 230 people across three offices in the UK, two in the US and one in Switzerland.

The deal was backed by UK-based private equity investor LDC, which has committed further equity to accelerate Fishawack's growth strategy, and see the exit of Growth Capital Partners (GCP) who supported the management team in a secondary buyout in 2013. 

Oliver Dennis, CEO of Fishawack, said: “With GCP's support we have made significant progress with our growth strategy over the past few years and bringing LDC alongside us will enable us to build on this further as we aim to create the largest independent player serving the growing global medical affairs market. 

“We have completed six acquisitions since inception and three with GCP, which has seen us bring in additional expertise, while also enhancing our geographical footprint in the key US market.”

In recent years the agency's acquisitions have included UK med comms agency Facilitate, US group JK Associates and Swiss agency Archimed.

Simon Braham, investment director at LDC in Manchester, said: “Global pharmacos continue to invest heavily in the research and development of new drugs, and with treatments and applications becoming increasingly complex there is a need to further educate healthcare professionals to ensure the efficacy, safety and ultimately benefits of new drugs are thoroughly understood, which help to make improved prescribing decisions to help patients. 

˙“Fishawack is very well-placed to meet this need and with the medical affairs industry valued at £6bn per year - almost 50% of which is outsourced – there is a clear opportunity to capitalise on.”

Article by
Dominic Tyer

25th January 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics